|1.||Jüppner, Harald: 8 articles (03/2013 - 02/2003)|
|2.||Imanishi, Yasuo: 6 articles (01/2012 - 05/2002)|
|3.||Miyauchi, Akimitsu: 4 articles (01/2012 - 04/2003)|
|4.||Miki, Takami: 4 articles (01/2012 - 04/2006)|
|5.||Inaba, Masaaki: 4 articles (01/2012 - 04/2006)|
|6.||Folpe, Andrew L: 3 articles (04/2013 - 01/2004)|
|7.||Hashimoto, Jun: 3 articles (01/2012 - 05/2004)|
|8.||Oba, Koichi: 3 articles (01/2012 - 04/2003)|
|9.||Ueda, Takafumi: 3 articles (01/2012 - 05/2004)|
|10.||Nagata, Yuki: 3 articles (01/2012 - 06/2010)|
05/01/2007 - "Oncogenic osteomalacia: induced by tumor, cured by surgery."
09/01/1999 - "Oncogenic osteomalacia is cured by resection of the responsible tumor. "
01/01/2012 - "The aim of this study is to discuss the pathophysiology of disease symptoms, pathomorphology of tumors, diagnostic methods and treatment of oncogenic osteomalacia."
12/01/1998 - "Tumor expression studies indicate that HEM-1 is unlikely to be the active factor in oncogenic osteomalacia."
08/01/2015 - "Phosphaturic mesenchymal tumor of the tibia with oncogenic osteomalacia in a teenager."
|2.||Paraneoplastic Syndromes (Paraneoplastic Syndrome)
04/01/2011 - "Oncogenic osteomalacia (OO) is a rare paraneoplastic syndrome, with only 100 reported cases in the literature. "
11/01/2008 - "Oncogenic osteomalacia, a rare paraneoplastic syndrome due to phosphate wasting--a case report and review of the literature."
04/01/2000 - "Oncogenic osteomalacia is a rare paraneoplastic syndrome. "
01/01/1999 - "Oncogenic osteomalacia is a rare paraneoplastic syndrome of skeletal demineralization from renal phosphate loss. "
01/01/1999 - "We report the first case of oncogenic osteomalacia that improved with chemotherapy, discuss this paraneoplastic syndrome, and review the medical literature regarding its etiology."
|3.||Metabolic Bone Diseases (Osteopenia)
11/01/2008 - "This series demonstrates that careful imaging of the nasal sinuses should be part of the work-up of cases of oncogenic osteomalacia, that serum FGF23 can be helpful in both diagnosis and monitoring treatment outcomes, and emphasizes that serum phosphate should be measured in patients with metabolic bone disease and/or unexplained musculoskeletal symptoms."
11/01/2008 - "Oncogenic osteomalacia (OOM) is a rare but curable cause of metabolic bone disease. "
09/01/2009 - "Oncogenic osteomalacia is a rare metabolic bone disease characterized by phosphate leakage from the kidney and subsequent hypophosphatemia. "
10/01/2011 - "Oncogenic osteomalacia is a rare metabolic bone disease characterized by phosphaturia and hypophosphatemia. "
05/01/2005 - "Oncogenic osteomalacia cured by removal of an organized hematoma."
05/01/2005 - "The symptoms and laboratory abnormalities of this patient with oncogenic osteomalacia promptly resolved after resection of an organized hematoma of the left hip."
05/01/2005 - "To describe a patient with oncogenic osteomalacia whose symptoms were rapidly resolved after surgical removal of an organized hematoma of the hip. "
|5.||X-Linked Dominant Hypophosphatemic Rickets (X-Linked Hypophosphatemia)
10/01/2011 - "Metabolic bone markers were examined in patients with oncogenic osteomalacia (OOM) and X-linked hypophosphatemic rickets (XLH), and in healthy controls. "
01/01/2010 - "Matrix extracellular phosphoglycoprotein (MEPE) is an inhibitor of mineralization in situ and in cell cultures where altered expression is associated with oncogenic osteomalacia and hypophosphatemic rickets. "
03/01/2006 - "Stone formers with renal phosphate leak showed lower FGF23, compared with patients with oncogenic osteomalacia and X-linked hypophosphatemic rickets [572.3 (235.9-908.7) RU/ml]. "
11/01/2004 - "Although increased levels of circulating FGF-23 were detected in patients with different phosphate-wasting disorders such as oncogenic osteomalacia (OOM) and X-linked hypophosphatemia (XLH), it is not yet clear whether FGF-23 is directly responsible for the abnormal regulation of mineral ion homeostasis and consequently bone development. "
04/24/2003 - "FGF-23 is readily detectable in the plasma or serum of healthy persons and can be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting that this growth factor has a role in phosphate homeostasis. "
|1.||Messenger RNA (mRNA)
|2.||fibroblast growth factor 23
|4.||Complementary DNA (cDNA)
|10.||Somatostatin Receptors (Somatostatin Receptor)
|1.||Drug Therapy (Chemotherapy)